AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7923659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 7923659 — intervention group
Group type: EXPERIMENTAL
Intervention: c7E3 Fab
Number of subjects: 56
Study 3197915 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin suppository
Number of subjects: 683
Study 3197915 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin suspension
Number of subjects: 683
Study 31079517 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle program with periodic group-based activities on healthy lifestyle behaviors
Number of subjects: 1903
Study 31079517 — intervention group
Group type: COMPARATOR
Intervention: One-time education program (control)
Number of subjects: 1903
Study 28241991 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (two 250‐mg tablets of magnesium oxide daily for 8 weeks)
Number of subjects: 60
Study 28241991 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two tablets daily for 8 weeks)
Number of subjects: 60
Study 25727810 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (2000‐4000 IU cholecalciferol) orally daily until delivery
Number of subjects: 78
Study 25727810 — intervention group
Group type: COMPARATOR
Intervention: No supplementation
Number of subjects: 78
Study 23595385 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Lumbar Disc Replacement (TDR)
Number of subjects: 68
Study 23595385 — intervention group
Group type: COMPARATOR
Intervention: Traditional fixation procedure (control)
Number of subjects: 68
Study 21345714 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline neck pain measured using the Northwick Park Neck Pain Questionnaire (NPQ)
Number of subjects: 151
Study 21345714 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline upper limb disability measured using the Disabilities of Arm, Shoulder, Hand questionnaire (DASH)
Number of subjects: 151
Study 19837094 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholera vaccine alone
Number of subjects: 3
Study 19837094 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholera vaccine plus zinc supplementation
Number of subjects: 3
Study 19837094 — intervention group
Group type: COMPARATOR
Intervention: Zinc alone
Number of subjects: 3
Study 19837094 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholera vaccine with zinc supplementation
Number of subjects: 3
Study 16476596 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced Duplex ultrasonography
Number of subjects: 20
Study 16476596 — intervention group
Group type: COMPARATOR
Intervention: CT angiography (CTA)
Number of subjects: 20
Study 15185303 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Injection Sclerotherapy (EIS)
Number of subjects: 50
Study 15185303 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic Band Ligation (EBL)
Number of subjects: 50
Study 15185303 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EIS and EBL
Number of subjects: 50
Study 15185303 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial HVPG greater than 16 mm Hg
Number of subjects: 50
Study 11499184 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol (50 micrograms)
Number of subjects: 60
Study 11499184 — intervention group
Group type: COMPARATOR
Intervention: Intravaginal prostaglandin E2 (4 mg)
Number of subjects: 60
Study 11499184 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Number of subjects: 60
Study 11499184 — intervention group
Group type: COMPARATOR
Intervention: Intravaginal prostaglandin E2
Number of subjects: 60
Study 9571345 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment arm aiming for normal HbA1c levels
Number of subjects: 153
Study 9571345 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase I: evening intermediate or long-acting insulin
Number of subjects: 153
Study 9571345 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase II: added daytime glipizide (up to 10 mg/day)
Number of subjects: 153
Study 9571345 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase III: two injections of insulin alone
Number of subjects: 153
Study 9571345 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase IV: multiple daily insulin injections
Number of subjects: 153
Study 9571345 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of glipizide and insulin (up to 20 mg/day)
Number of subjects: 153
Study 9571345 — intervention group
Group type: EXPERIMENTAL
Intervention: Home glucose monitoring
Number of subjects: 153
Study 7835326 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity exercise
Number of subjects: 23
Study 7835326 — intervention group
Group type: EXPERIMENTAL
Intervention: Long duration high intensity exercise
Number of subjects: 23
Study 7835326 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 23
Study 2896425 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% phenylephrine
Number of subjects: 10
Study 2896425 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% thymoxamine
Number of subjects: 10
Study 2896425 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% thymoxamine + 10% phenylephrine
Number of subjects: 10
Study 2896425 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% isoproterenol
Number of subjects: 10
Study 2896425 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol
Number of subjects: 10
Study 2896425 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% betaxolol
Number of subjects: 10
Study 2896425 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 10
Study 2896425 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-luminance myopia
Number of subjects: 10
Study 30375382 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbapenem hydrolysis
Number of subjects: 0
Study 30375382 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin hydrolysis
Number of subjects: 0
Study 30375382 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalosporin hydrolysis
Number of subjects: 0
Study 26851605 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental intervention (ten face-to-face educational sessions)
Number of subjects: 150
Study 26851605 — intervention group
Group type: COMPARATOR
Intervention: Minimal control intervention (mailed information)
Number of subjects: 150
Study 25586759 — intervention group
Group type: EXPERIMENTAL
Intervention: Interspinous process devices (IPD)
Number of subjects: 159
Study 25586759 — intervention group
Group type: COMPARATOR
Intervention: Bony decompression
Number of subjects: 159
Study 24021517 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (100 μg twice weekly) with cyclic progesterone
Number of subjects: 72
Study 24021517 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches and pills
Number of subjects: 72
Study 20869812 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 642
Study 20869812 — intervention group
Group type: COMPARATOR
Intervention: Nicotine lozenge
Number of subjects: 642
Study 18372276 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin for long-term secondary prevention of VTE
Number of subjects: 0
Study 18372276 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated and low-molecular-weight heparins for primary prophylaxis
Number of subjects: 0
Study 18372276 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk assessment for prophylaxis decision-making
Number of subjects: 0
Study 12352277 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment (sertraline, desipramine)
Number of subjects: 46
Study 12352277 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 46
Study 9583291 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial cells
Number of subjects: 0
Study 9583291 — intervention group
Group type: COMPARATOR
Intervention: Mitogens concanavalin‐A and phytohaemagglutinin‐P
Number of subjects: 0
Study 8126147 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (125 mg, 12 times/24 h)
Number of subjects: 8
Study 2768614 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving skills training (PSST)
Number of subjects: 112
Study 2768614 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving skills training with in vivo practice (PSST-P)
Number of subjects: 112
Study 2768614 — intervention group
Group type: COMPARATOR
Intervention: Client-centered relationship therapy (RT)
Number of subjects: 112
Study 886043 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-positive milieu
Number of subjects: 42
Study 886043 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-negative milieu
Number of subjects: 42
Study 886043 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture-positive milieu
Number of subjects: 42
Study 886043 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture-negative milieu
Number of subjects: 42
Study 886043 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and placebo acupuncture
Number of subjects: 42
Study 31840815 — intervention group
Group type: EXPERIMENTAL
Intervention: SIRT + FOLFOX
Number of subjects: 1103
Study 31840815 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX alone
Number of subjects: 1103
Study 27862950 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17β‐oestradiol (E2) 0.15 mg
Number of subjects: 11
Study 27862950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 25819860 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 5.0 mg twice daily
Number of subjects: 2995
Study 25819860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2995
Study 23594968 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg loading dose of prasugrel
Number of subjects: 30
Study 23594968 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg loading dose of prasugrel
Number of subjects: 30
Study 23594968 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg maintenance dose of prasugrel
Number of subjects: 30
Study 23594968 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg maintenance dose of prasugrel
Number of subjects: 30
Study 23594968 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg maintenance dose of prasugrel
Number of subjects: 30
Study 23594968 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily 5 mg doses of prasugrel
Number of subjects: 30
Study 23594968 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg, 7.5 mg, and 5 mg doses of prasugrel
Number of subjects: 30
Study 20494865 — intervention group
Group type: EXPERIMENTAL
Intervention: Mimicry (imitation of nonverbal behavior)
Number of subjects: 0
Study 20494865 — intervention group
Group type: COMPARATOR
Intervention: Nonmimicry (control group)
Number of subjects: 0
Study 19559143 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held personal digital assistant (PDA)
Number of subjects: 26
Study 19559143 — intervention group
Group type: COMPARATOR
Intervention: Traditional written records
Number of subjects: 26
Study 16636528 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (performing a second and a third PR after 6 and 12 months)
Number of subjects: 35
Study 16636528 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (performing only a second PR after 12 months)
Number of subjects: 35
Study 16636528 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1
Number of subjects: 35
Study 16259438 — intervention group
Group type: EXPERIMENTAL
Intervention: Bestim
Number of subjects: 0
Study 11329784 — intervention group
Group type: EXPERIMENTAL
Intervention: 5'‐DFUR + LV (leucovorin)
Number of subjects: 62
Study 11329784 — intervention group
Group type: COMPARATOR
Intervention: 5'‐DFUR alone
Number of subjects: 62
Study 9209661 — intervention group
Group type: EXPERIMENTAL
Intervention: Five courses of carboplatin 400 mg/m2 or cisplatin 75 mg/m2
Number of subjects: 225
Study 9209661 — intervention group
Group type: COMPARATOR
Intervention: Eight courses of carboplatin 400 mg/m2 or cisplatin 75 mg/m2
Number of subjects: 225
Study 8429800 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (2 mg oestradiol (E2) and 1 mg norethisterone acetate (NETA) daily)
Number of subjects: 151
Study 8429800 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy (2 mg E2 for 12 days, 2 mg E2 and 1 mg NETA for 10 days, and 1 mg E2 for 6 days)
Number of subjects: 151
Study 8429800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 29984601 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg
Number of subjects: 0
Study 29984601 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg
Number of subjects: 0
Study 29984601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27742464 — intervention group
Group type: EXPERIMENTAL
Intervention: IRB300 + ATO40
Number of subjects: 230
Study 27742464 — intervention group
Group type: EXPERIMENTAL
Intervention: IRB300 + ATO80
Number of subjects: 230
Study 27742464 — intervention group
Group type: COMPARATOR
Intervention: ATO40
Number of subjects: 230
Study 27742464 — intervention group
Group type: COMPARATOR
Intervention: ATO80
Number of subjects: 230
Study 27742464 — intervention group
Group type: COMPARATOR
Intervention: IRB300
Number of subjects: 230
Study 27742464 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 230
Study 25361615 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfiltered rides (exposed to TRAPs)
Number of subjects: 21
Study 25361615 — intervention group
Group type: COMPARATOR
Intervention: Filtered rides (not exposed to TRAPs)
Number of subjects: 21
Study 25361615 — intervention group
Group type: EXPERIMENTAL
Intervention: Particle number concentration increase
Number of subjects: 21
Study 22525910 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomegestrol acetate (2.5 mg) and 17β‐E2 (1.5 mg) in a 24‐4‐day regimen
Number of subjects: 2281
Study 22525910 — intervention group
Group type: COMPARATOR
Intervention: Drospirenone (3.0 mg) and ethinyl E2 (30 micrograms) in a 21‐7‐day regimen
Number of subjects: 2281
Study 20443094 — intervention group
Group type: EXPERIMENTAL
Intervention: FAST (weight loss > or = 0.68 kg/week, n = 69)
Number of subjects: 262
Study 20443094 — intervention group
Group type: EXPERIMENTAL
Intervention: MODERATE (weight loss > or = 0.23 and < 0.68 kg/week, n = 104)
Number of subjects: 262
Study 20443094 — intervention group
Group type: COMPARATOR
Intervention: SLOW (weight loss < 0.23 kg/week, n = 89)
Number of subjects: 262
Study 20443094 — intervention group
Group type: EXPERIMENTAL
Intervention: FAST and MODERATE groups
Number of subjects: 262
Study 20443094 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 262
Study 20635912 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with heat-killed Mycobacterium vaccae (SRL172)
Number of subjects: 0
Study 16856574 — intervention group
Group type: COMPARATOR
Intervention: Epidural spinal cord stimulation (SCS)
Number of subjects: 18
Study 12538037 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 48
Study 12538037 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprorelin acetate depot
Number of subjects: 48
Study 12538037 — intervention group
Group type: COMPARATOR
Intervention: Control group (women without endometriosis)
Number of subjects: 48
Study 10868467 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 0
Study 10868467 — intervention group
Group type: COMPARATOR
Intervention: Divalproex
Number of subjects: 0
Study 10868467 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9083239 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin 4% + hydroxyethylstarch 6%
Number of subjects: 27
Study 9083239 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin 4% + dextran 40
Number of subjects: 27
Study 9083239 — intervention group
Group type: COMPARATOR
Intervention: Albumin 4% alone
Number of subjects: 27
Study 9083239 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin 4% + hydroxyethylstarch 6% or dextran 40
Number of subjects: 27
Study 8410927 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg twice daily)
Number of subjects: 13
Study 8410927 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg once daily)
Number of subjects: 13
Study 3739820 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of nicotine
Number of subjects: 0
Study 3739820 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of nicotine
Number of subjects: 0
Study 3739820 — intervention group
Group type: EXPERIMENTAL
Intervention: Not smoking
Number of subjects: 0
Study 3739820 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsmokers
Number of subjects: 0
Study 31390314 — intervention group
Group type: COMPARATOR
Intervention: Sandblasting (50 μm alumina particles)
Number of subjects: 50
Study 31390314 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser irradiation at 2 W
Number of subjects: 50
Study 31390314 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser irradiation at 1 W
Number of subjects: 50
Study 31390314 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser irradiation at 3 W
Number of subjects: 50
Study 31390314 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 50
Study 29923910 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic exercise training (FiO2 15%)
Number of subjects: 14
Study 29923910 — intervention group
Group type: COMPARATOR
Intervention: Normoxic exercise training
Number of subjects: 14
Study 26844926 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled allergen
Number of subjects: 0
Study 25227477 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy during labor
Number of subjects: 156
Study 25227477 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music)
Number of subjects: 156
Study 22456770 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 23
Study 22456770 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 23
Study 20332142 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus (25 mg)
Number of subjects: 626
Study 20332142 — intervention group
Group type: COMPARATOR
Intervention: Temsirolimus (15 mg) + IFN-alpha
Number of subjects: 626
Study 20332142 — intervention group
Group type: COMPARATOR
Intervention: IFN-alpha
Number of subjects: 626
Study 17509313 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium-magnesium citrate (42 mEq potassium, 21 mEq magnesium, 63 mEq citrate per day)
Number of subjects: 20
Study 17509313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15741846 — intervention group
Group type: COMPARATOR
Intervention: Control trial (accurate feedback at each kilometer split)
Number of subjects: 15
Study 15741846 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase trial (inaccurate feedback starting at 0.775 km, increasing by 25 m each split)
Number of subjects: 15
Study 15741846 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease trial (inaccurate feedback starting at 1.25 km, decreasing by 25 m each split)
Number of subjects: 15
Study 15741846 — intervention group
Group type: EXPERIMENTAL
Intervention: Random trial (randomized distance splits)
Number of subjects: 15
Study 11839621 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative, ischemia-guided strategy
Number of subjects: 876
Study 11839621 — intervention group
Group type: COMPARATOR
Intervention: Routine invasive strategy
Number of subjects: 876
Study 10081528 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1 g given rectally
Number of subjects: 140
Study 10081528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 7567210 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold air hyperventilation (CAH)
Number of subjects: 17
Study 7567210 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled methacholine (MCH)
Number of subjects: 17
Study 2210246 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 102
Study 2210246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 6778324 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin V (55 mg/kg/day)
Number of subjects: 149
Study 6778324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 6778324 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V (55 mg/kg/day) and Placebo
Number of subjects: 149
Study 30535345 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted electronic health record (EHR) alert
Number of subjects: 1021
Study 30535345 — intervention group
Group type: COMPARATOR
Intervention: Control (no EHR alert)
Number of subjects: 1021
Study 28790113 — intervention group
Group type: EXPERIMENTAL
Intervention: SR48692 (NTSR1 antagonist) combined with carboplatin
Number of subjects: 0
Study 28790113 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin alone
Number of subjects: 0
Study 25801542 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg intravenous fosaprepitant (NKI group)
Number of subjects: 44
Study 25801542 — intervention group
Group type: COMPARATOR
Intervention: 4 mg ondansetron (ONS group)
Number of subjects: 44
Study 22578715 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological flexibility (assessed by AAQ‐II)
Number of subjects: 30
Study 22578715 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness (assessed by KIMS)
Number of subjects: 30
Study 21824612 — intervention group
Group type: EXPERIMENTAL
Intervention: Cap-assisted colonoscopy (CAC)
Number of subjects: 329
Study 21824612 — intervention group
Group type: COMPARATOR
Intervention: Regular colonoscopy (RC)
Number of subjects: 329
Study 19302271 — intervention group
Group type: EXPERIMENTAL
Intervention: Cue location validity
Number of subjects: 0
Study 19302271 — intervention group
Group type: COMPARATOR
Intervention: Background luminance
Number of subjects: 0
Study 19302271 — intervention group
Group type: EXPERIMENTAL
Intervention: Location vs. color
Number of subjects: 0
Study 17410046 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 134
Study 17410046 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Number of subjects: 134
Study 17410046 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 134
Study 12464713 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine up to 20 mg/day
Number of subjects: 16
Study 12464713 — intervention group
Group type: COMPARATOR
Intervention: Piracetam up to 1,200 mg/day
Number of subjects: 16